Treatment response in COPD: does FEV 1 say it all? A post hoc analysis of the CRYSTAL study.
Autor: | Kostikas K; Respiratory Medicine Dept, University of Ioannina, Ioannina, Greece., Greulich T; Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Giessen, Germany., Mackay AJ; Airways Disease Section, National Heart and Lung Institute, Imperial College London, London, UK., Lossi NS; Novartis Pharma GmbH, Nuremberg, Germany., Aalamian-Mattheis M; Novartis Pharma AG, Basel, Switzerland., Nunez X; TFS Develop, Barcelona, Spain., Pagano VA; TFS Develop, Barcelona, Spain., Patalano F; Novartis Pharma AG, Basel, Switzerland., Clemens A; Novartis Pharma AG, Basel, Switzerland.; Dept of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.; These two authors contributed equally to this work., Vogelmeier CF; Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Giessen, Germany.; These two authors contributed equally to this work. |
---|---|
Jazyk: | angličtina |
Zdroj: | ERJ open research [ERJ Open Res] 2019 Feb 25; Vol. 5 (1). Date of Electronic Publication: 2019 Feb 25 (Print Publication: 2019). |
DOI: | 10.1183/23120541.00243-2018 |
Abstrakt: | The association between clinically relevant changes in patient-reported outcomes (PROs) and forced expiratory volume in 1 s (FEV Competing Interests: Conflict of interest: K. Kostikas was an employee of Novartis until October 31, 2018. Conflict of interest: T. Greulich reports receiving support from Novartis for participation as a centre in the current the study; and personal fees for lectures and advisory boards from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Chiesi, CSL Behring, GSK and Novartis, grants and personal fees for lectures and advisory boards from Grifols, and grants from the German Centre for Lung Research (DZL), Marburg, Germany, outside the submitted work. Conflict of interest: A.J. Mackay was a European Respiratory Society Fellow in Industry at Novartis during the preparation of the manuscript. He is a current employee of AstraZeneca and has received speaker fees from Pfizer outside the submitted work. Conflict of interest: N.S. Lossi is currently an employee of Novartis Pharma GmbH. Conflict of interest: M. Aalamian-Mattheis is an employee of Novartis Pharma AG. Conflict of interest: X. Nunez analysed the data in the present study as a statistician employed by TFS. Conflict of interest: V.A. Pagano analysed the data in the present study as a statistician employed by TFS. Conflict of interest: F. Patalano is an employee and a shareholder of Novartis Pharma AG. Conflict of interest: A. Clemens is a full-time employee and shareholder at Novartis Pharma AG. Conflict of interest: C.F. Vogelmeier reports personal fees from Almirall, Cipla, Berlin-Chemie/Menarini, CSL Behring and Teva, grants and personal fees from AstraZeneca, Ingelheim, Chiesi, GSK, Grifols, Mundipharma, Novartis and Takeda, grants from German Federal Ministry of Education and Research (BMBF) Competence Network Asthma and COPD (ASCONET), Bayer Schering Pharma AG, MSD and Pfizer, outside the submitted work. |
Databáze: | MEDLINE |
Externí odkaz: |